Evidence map›Paper›PMID 38817681›Full record

ArticleMolecular therapy. Nucleic acids2024

SAP30, an oncogenic driver of progression, poor survival, and drug resistance in neuroblastoma.

Philip Prathipati, Anup S Pathania, Nagendra K Chaturvedi, Subash C Gupta, Siddappa N Byrareddy, Don W Coulter, Kishore B Challagundla

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. A comprehensive survey of genetic variants in neuroblastoma.Journal, genetic engineering & biotechnology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. miR-15a and miR-15b modulate natural killer and CD8Molecular therapy oncolytics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Philip PrathipatiLaboratory of Bioinformatics, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saito-Asagi, Ibaraki City, Osaka 567-0085, Japan.
Anup S PathaniaDepartment of Biochemistry and Molecular Biology & Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Nagendra K ChaturvediDepartment of Pediatrics, Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Subash C GuptaDepartment of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India.
Siddappa N ByrareddyDepartment of Biochemistry and Molecular Biology & Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Don W CoulterDepartment of Pediatrics, Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Kishore B ChallagundlaDepartment of Biochemistry and Molecular Biology & Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Funding

Exosomic microRNAs and drug resistance in AML tumor microenvironmentK22CA197074 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CHALLAGUNDLA, KISHORE B. · 2016 to 2018
$465k
NCI NIH HHS K22 CA197074
6 · The paper itself

Abstract

Neuroblastoma is the most devastating extracranial solid malignancy in children. Despite an intense treatment regimen, the prognosis for high-risk neuroblastoma patients remains poor, with less than 40% survival. So far,

Indexed as

chemotherapy responseCRISPR-Cas9 screenhigh-risk neuroblastomaMT: bioinformaticsMYCNpatient-derived xenograftspharmacogenomic analysisprognosisSAP30survival

Identifiers

PMID38817681
PMCPMC11137595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.